Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
Go back to Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 9.03 +0.47 (5.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.56 | 52 Week High | $9.23 | |||
| Open | $8.54 | 52 Week Low | $1.16 | |||
| Day High | $9.09 | P/E | N/A | |||
| Day Low | $8.45 | EPS | $-0.30 | |||
| Volume | 3,572,984 | |||||
